Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bacteriophage-mediated nucleic acid immunisation.

Jason R Clark1, John B March

  • 1Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, UK.

FEMS Immunology and Medical Microbiology
|January 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical argument for establishing good manufacturing practice for phage therapy in the UK.

Journal of medical ethics·2024
Same author

Phage Therapy for Diabetic Foot Infection: A Case Series.

Clinical therapeutics·2023
Same author

The Future of Clinical Phage Therapy in the United Kingdom.

Viruses·2023
Same author

Quality and safety requirements for sustainable phage therapy products.

Pharmaceutical research·2015
Same author

Inactivation of recombinant bacteriophage lambda by use of chemical agents and UV radiation.

Applied and environmental microbiology·2012
Same author

Protection of mice against Chlamydophila abortus infection with a bacteriophage-mediated DNA vaccine expressing the major outer membrane protein.

Veterinary immunology and immunopathology·2011

Bacteriophage lambda particles effectively deliver genes for vaccines, inducing strong immune responses. This novel DNA vaccine platform offers advantages like enhanced antigen presentation and cost-effective production.

Area of Science:

  • Molecular Biology
  • Immunology
  • Virology

Background:

  • Nucleic acid immunization is a promising vaccine strategy.
  • Bacteriophage lambda particles offer a potential delivery system for genetic material.

Purpose of the Study:

  • To evaluate bacteriophage lambda as a delivery vehicle for DNA vaccines.
  • To assess the immunogenicity and antigen-presenting cell targeting capabilities of bacteriophage-based vaccines.

Main Methods:

  • Whole bacteriophage lambda particles containing reporter genes (e.g., HBsAg, GFP) under the cytomegalovirus promoter (P(CMV)) were constructed.
  • Mice were intramuscularly injected with bacteriophage carrying the hepatitis B surface antigen (HBsAg) gene.
  • Isolated peritoneal macrophages were incubated with bacteriophage carrying the green fluorescent protein (GFP) gene.

Related Experiment Videos

Main Results:

  • Intramuscular injection of HBsAg-encoding bacteriophage induced high anti-HBsAg antibody responses (>150 mIU ml(-1)).
  • Bacteriophage carrying GFP resulted in detectable GFP antigen on macrophage surfaces within 8 hours.
  • These findings suggest direct targeting of antigen-presenting cells by bacteriophage vaccines.

Conclusions:

  • Bacteriophage lambda particles serve as effective delivery vehicles for DNA vaccines, potentially enhancing immune responses.
  • This platform offers advantages including large cloning capacity, DNA protection, potential for oral delivery, and cost-effective production.
  • Bacteriophage DNA vaccines represent a promising alternative to traditional vaccine delivery methods.